STERIS (STE) Stock Hits New 52-Week High: What's Driving It?
Zacks Investment Research | Feb 26, 2020 05:17AM ET
Shares of STERIS plc (NYSE:STE) reached a new 52-week high of $168.98 on Feb 25, before closing the session marginally lower at $164.87. The stock has rallied 7.4% since its fiscal 2020 third-quarter earnings announcement on Feb 10.
The company is witnessing an upward trend in its stock price, prompted by contributions from elevated consumer demand. A broader portfolio of products and services along with several tuck-in acquisitions bodes well. Further, solid performance by each of its key operating businesses in the third quarter of fiscal 2020 boosted the market sentiment. A raised company guidance instills investors’ optimism.
Let's delve deeper.
Q3 Performance
STERIS exited third-quarter fiscal 2020 with better-than-expected results. The company witnessed solid revenue growth across each of its operating segments, which is encouraging. Contributions from elevated consumer demand, and a broader portfolio of products and services bode well. Expansion of both margins during the quarter is also encouraging. Additionally, increased fiscal 2020 guidance instills investors’ confidence in the stock.
Other Growth Drivers
Potential of Infection Prevention and Sterilization Wing: Investors are upbeat about STERIS’ continued benefits from the acquisition of Synergy Health — the U.K.-based outsourced sterilization services provider — as it paves the way for STERIS’ global leadership in infection prevention and sterilization. The sector recorded solid revenue growth from strong adoptions by the company’s global core medical device customer base.
The consolidation boosted STERIS' presence in the international markets as it combines the company’s strong presence in North America with Synergy's solid footprint across Europe. It also provided STERIS with an opportunity to better serve the emerging markets of the Asia Pacific and Latin America.
Healthcare and Pharmaceutical Industries Hold Potential: Investors are optimistic about the growth potential of the company in the healthcare and pharmaceutical industries. With life expectancy is on the rise globally, a larger aging population increases the demand for medical procedures. This, in turn, translates into higher consumption of single-use medical devices and surgical kits processed by STERIS.
However, despite the upsides, the company’s stock price may witness a downturn due to several customers undergoing consolidation. This partly resulted from healthcare cost-reduction measures initiated by competitive pressures as well as legislators, regulators and third-party payors. The company also faces tough competition from big-shots like Johnson & Johnson (NYSE:JNJ) as well as small companies. The continued efforts of the government and insurance companies to contain the rising cost of healthcare are also putting pressure on STERIS’ financial operations.
Get The News You Want
Zacks Rank & Other Key Picks
Currently, the company carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health Corp. (NASDAQ:PAHC) , Hill-Rom Holdings, Inc. (NYSE:HRC) and ResMed Inc. (NYSE:RMD) .
Phibro currently sports a Zacks Rank #1 (Strong Buy) and has a projected long-term earnings growth rate of 2.1%. You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.